Epigral Share Price

Epigral Limited manufactures and sells chlor-alkali and related derivatives in India and internationally. Its products are used in CPVC pipes and fittings, windmills, construction, paints and coatings, electronics, water treatment, agrochemicals, etc. The company was formerly known as Meghmani Finechem Limited and changed its name to Epigral Limited. Epigral share price on the NSE and BSE is a reflection of how market participants respond to a company’s performance and broader business developments within its industry. It captures the sentiment of the investors based on financial results, operational updates, macroeconomic factors, and trends specific to sectors. Movements in the share price͏ reveal how the market evaluates the company’s current position and its future prospects, making ͏it a key indicator of market perception across various industries.

The Epigral stock price is influenced by various factors such as earnings, product realizations, raw material costs, plant utilization rates, and regulatory changes. In the longer run, strategies such as capacity expansion, product mix improvement, and operational efficiency affect stock market sentiments. All these factors must be closely monitored to have an idea about the Epigralstock price movements.

Epigrallive share price provides real-time information about the last price traded, bid price, ask price, and volume traded. These indicators represent trading activity and liquidity and the reaction of investors to corporate announcements, quarterly results, and sector news. Constant ͏monitoring of Epigrallive price helps observe short-term price fluctuations and understand how the stock is moving in relation to the broader market.

Furthermore, monitoring the Epigral share͏ price today helps investors understand real-time market sentiment, price volatility, and trading behaviour. It allows market participants to evaluate short-term performance, identify possible entry or exit points, and respond to news, quarterly results or sector trends that may affect the company’s valuation and overall investment outlook.

Epigral Limited Company Fundamentals

Epigral Company Background

Epigral was incorporated in 2007 and operates in India’s chemical manufacturing sector as an integrated producer of basic and specialty chemicals. The company commenced operations with Chlor-Alkali products at the Dahej PCPIR region in Gujarat. Over time, it expanded into Chloromethanes, Hydrogen Peroxide, Epichlorohydrin, and CPVC, following an integrated chemical complex approach to improve resource utilisation and operational efficiency. Its manufacturing facility is fully automated and designed to support continuous production across chemical segments. Epigral commissioned India’s first Epichlorohydrin plant based on renewable raw materials and established a CPVC production unit to meet infrastructure-related demand. The company is currently developing capacities in the Chlorotoluene value chain and related downstream chemicals. An in-house research and development centre supports process optimisation and specialty chemical development. Over the years, Epigral has transitioned from basic chemical manufacturing to a diversified product portfolio serving sectors such as construction, pharmaceuticals, agrochemicals, and industrial manufacturing. Its operations emphasise integrated production, capacity expansion, regulatory compliance, and consistent supply across domestic and international markets while maintaining safety, environmental standards, and operational continuity.

Epigral Company Product Lines

Chlor-Alkali and Basic Chemicals

• Caustic Soda
• Caustic Potash
• Chlorine
• Hydrogen
• Related chlor-alkali derivatives

Chloromethanes (CMS)

• Methyl Chloride
• Methylene Chloride (MDC)
• Chloroform
• Carbon Tetrachloride

Hydrogen Peroxide (H₂O₂)

• Industrial oxidizer for paper, textiles, effluent treatment, etc.

Epichlorohydrin (ECH)

• Including renewable glycerin-based ECH for epoxy and other chemicals

CPVC Products

• CPVC Resin
• CPVC Compound

Chlorotoluenes Value Chain

• Integrated intermediates for agrochemical & pharmaceutical applications

Epigral Limited Company Revenue Model

Epigral’s revenue streams are generated through:

• Product Sales

• • Sales of Chlor-Alkali chemicals and derivatives to industrial customers.

• • Sale of specialty products such as CPVC resin & compound, epichlorohydrin, chloromethanes, and hydrogen peroxide.

Integrated Value Chain Advantage

• Backward and forward integration helps reduce raw material costs and improves margins, as chlorine and hydrogen from basic production feed downstream units.

Industry Diversification

• Revenue depends on diverse end users such as construction, textiles, pulp & paper, agrochemicals, electronics, and water treatment sectors.

Domestic & Export Sales

• Majority revenue from domestic sales with select export markets.

Segment Contribution

• Derivatives & Specialty Chemicals contribute a larger share than basic Chlor-Alkali, reflecting value-added product focus.

Epigral Geographic Presence

Manufacturing Facilities

• Integrated chemical complex located in Dahej, Gujarat, India (PCPIR region).

R&D Centre

• Research and development centre in Sanand, Ahmedabad, Gujarat.

Corporate and Business Offices

• Headquarters and corporate office in Ahmedabad, with business presence in major Indian cities.
• Mumbai and Hyderabad Offices

Industries Served

• Over 15 downstream sectors including construction, pharmaceuticals, textiles, paper & pulp, soap & detergents, water treatment, and more

Epigral Leadership 

Some of the key leaders of Epigral Limited as of February 2026 are

• Maulik Patel — Chairman & Managing Director
• Kaushal Soparkar — Executive Director
• Ankit Patel — Non-Executive Director
• Karana Patel — Non-Executive Director
• Darshan Patel — Non-Executive Director
• Manu Patel — Independent Director
• Sanjay Asher — Independent Director
• Kanu Patel — Independent Director
• Raju Swamy — Independent Director
• Priyanka Chopra — Independent Director

Epirgral Limited Key Milestones

• 2007 – Incorporated as Meghmani Finechem Limited, a subsidiary of Meghmani Organics Limited, engaged in manufacturing Chlor-Alkali & derivatives and trading agrochemical products.
• 2009 – Commissioned initial Chlor-Alkali business.
• 2015 – Chlor-Alkali installed capacity reached 1,88,000 TPA.
•  2020-21 – Chlor-Alkali capacity expanded to 3,15,000 TPA.
• 2021 – Demerged from Meghmani Organics Limited as a going concern through Scheme of Arrangement.
• 2021 – Allotted 2,39,03,029 equity shares to shareholders of Meghmani Organics Limited.
• 2020 – Caustic Soda capacity expanded by 1,27,000 TPA to 2,94,000 TPA; Captive Power Plant capacity increased by 36 MW to 96 MW.
• 2020 – Commissioned 60,000 TPA Hydrogen Peroxide plant.
• 2022 – Commissioned Epichlorohydrin (ECH) plant with 50,000 TPA capacity.
• 2022 – Commissioned CPVC Resin plant with 30,000 TPA capacity.
• 2022 – Expanded Caustic Soda capacity to 400 KTPA and Captive Power Plant by 36 MW.
• 2024 – Commissioned additional 45,000 TPA CPVC Resin capacity, total 75,000 TPA.
• 2024 – Commissioned CPVC Compound facility of 35,000 TPA.
• 2025 – Announced further 75,000 TPA CPVC Resin expansion, total capacity 1,50,000 TPA.
• 2025 – Commissioned India’s first Chlorotoluenes Value Chain Facility at Dahej, Gujarat.

Industry Perspective

Epigral Limited operates within the chemical industry, specifically in segments such as chlor-alkali chemicals, derivatives, epichlorohydrin, CPVC, and related intermediates. The chemical sector is a major component of India’s economy and global manufacturing ecosystem. India is the sixth largest chemical producer in the world and the third largest in Asia, with the industry contributing approximately 7 % to India’s GDP and producing a wide spectrum of basic and specialty chemicals. The Indian chemical market is estimated at roughly ₹21.5 lakh crore (US$ 250 billion) in 2024 and is projected to grow to US$ 300 billion by 2028 and potentially reach US$ 1 trillion by 2040, supported by rising domestic demand and export opportunities.

Specialty chemicals, which include higher value products and derivatives, reached about US$ 64.5 billion in 2024 and are expected to grow to around US$ 92.6 billion by 2033 at a CAGR of about 3.8 %. The chlo-ralkali segment remains fundamental for industrial feedstocks, with global market estimates suggesting it could expand from approximately US$ 99 billion in 2025 toward US$ 278 billion by 2035 at a CAGR near 10 %. Overall, the chemical industry’s growth is driven by urbanisation, infrastructure development, industrialisation, and supply chain diversification as companies seek alternatives to traditional hubs.

Epigral Limited stands to benefit from the chemical industry’s growth through its integrated production model and diverse product portfolio, including chlor-alkali, epichlorohydrin, CPVC, and specialty chemicals. Rising domestic demand, infrastructure expansion, and increasing specialty chemical consumption can boost revenues, optimise margins, and strengthen market presence, positioning Epigral to capitalise on both domestic and export opportunities in a growing sector.

Epigral Limited Stock Market Presence: Listings & Index Representation

Epigral Limited listed on the NSE (National Stock Exchange) on July 27, 2021, and on the BSE (Bombay Stock Exchange) on August 18, 2021, following its initial public offering.

Epigral Limited is an established entity in the Indian stock market, listed on major exchanges such as NSE (EPIGRAL) and BSE (543596). Its inclusion in prominent indices like Nifty Microcap 250, S&P BSE SmallCap, S&P BSE Basic Materials, S&P BSE MidSmallCap, S&P BSE AllCap, Nifty Total Market, and BSE 1000 underscores the company’s significance in India’s chemical manufacturing sector.

The Epigral stock price is tracked by investors. Its inclusion in these indices reflects its market capitalisation and scale in chlor-alkali and derivative chemicals. Listing on NSE and BSE ensures liquidity, while index presence drives institutional holdings and benchmark tracking in the chemicals sector.

Epigral Limited Stock Performance and Share Price History

The Epigral share price on NSE and BSE reflects its position as a leading chemical manufacturer. Performance is driven by product pricing, feedstock costs, capacity utilization, and demand cycles across user industries. Investors compare the Epigral share price today with sectoral indices and peer companies to gauge relative performance.

These underlying factors are often visible through real market movements across different periods. Similar trends are observed during earnings-driven movements. Broader sector strength has also played a role in supporting the Epigral share price. In addition to operational and sector-led factors, corporate actions can also have a significant impact on Epigral share price movements short-term even when a company’s fundamentals remain strong. This shows how corporate actions can trigger short-term swings within a framework influenced by commodity cycles, input costs, and regulations.

While short-term movements reflect events and announcements, longer-term valuation trends are visible through Epigral share price 52-week high and low, providing context beyond daily or weekly changes. The 52-week high of ₹2,114 and low of ₹904.6 capture impacts of market cycles, growth expectations, margin pressures, and earnings visibility, providing context for the stock’s historical performance.

Epigral’s stock performance reflects the trading behaviour of a chemical company. The company’s diversified product portfolio, integrated operations, and focus on chlor-alkali derivatives have shaped its Epigral share price history. Over time, the stock has shown significant volatility, marked by periods of sharp gains and phases of correction.

The Epigral share price history since its listing shows distinct phases influenced by sector cycles and company-specific developments. Following its IPO in 2021, the Epigral stock price witnessed strong growth, with a 91.66% return in Q3 2021, driven by high chemical prices and strong investor interest. The year 2022 saw the Epigral share price deliver a 64.56% annual return, supported by robust earnings. However, the Epigral stock price faced pressure in 2023, declining 21.46% for the year, influenced by normalizing product margins and broader market corrections.

Epigral’s stock performance over time has followed chemical sector and economic cycles. For instance, the Epigral share price reached an all-time high above ₹2,400 in 2023, supported by peak profitability. Over longer investment horizons, the stock has delivered meaningful returns, including a significant gain of 642.57% over five years, highlighting growth aligned with capacity expansion. The Epigral share price decreased 43.79% over one year and 39.53% over three months, primarily due to corrections from previous highs, cyclical downturns in chemical margins, and increased market volatility. The Epigral stock price decline of 47.52% over six months and 17.6% over one month reflects ongoing sectoral headwinds and investor sentiment.

Despite market disruptions, Epigral shares have shown resilience over the long term. While the chemical sector faces pricing volatility, prudent management and operational efficiency have contributed to long-term value. The Epigral share price stability is influenced by consistent capacity utilization and a stable financial structure, keeping shares responsive to sector recoveries and market movements.

Epigral Limited Investor Relevance and Portfolio Role

Epigral is a holding in sector-specific and small-cap portfolios, offering exposure to chlor-alkali, epoxy, and chloromethane chemicals. Inclusion in indices like S&P BSE Basic Materials and Nifty Microcap 250 underscores its economic and strategic importance. Integrated operations, a diversified product slate, and market positioning make it a choice for thematic institutional allocations.

Epigral equity is held by a mix of domestic and international institutional investors, reflecting its position in India’s chemical sector. Top institutional stakeholders include HSBC Global Asset Management (UK) Limited, VLS Finance Limited, Bandhan AMC Limited, Dimensional Fund Advisors LP, BlackRock, Inc., American Century Investment Management Inc, Motilal Oswal Asset Management Company Limited, State Street Global Advisors, Inc., BNY Asset Management, and the Investor Education and Protection Fund (IEPF).

Prominent mutual fund holders include schemes from Bandhan AMC and Motilal Oswal Asset Management. This investor base underscores the company’s role as a holding in sector-focused portfolios.

Beyond fundamentals and ownership, Epigral’s stock is monitored in derivatives markets, where open interest and F&O quotes reflect expectations on product spreads, volume growth, and input costs. Technical indicators such as Epigral RSI, MACD, and MFI provide additional insight into short-term momentum shifts in Epigral stock price. While primarily used for near-term trading, these tools can also help gauge market sentiment and potential volatility around major events.

Epigral’s beta indicates its volatility relative to the market. The long-term beta is 1.20. Over shorter periods, beta values show higher volatility, with a daily one-month beta of 2.92 and a daily three-month beta of 2.05. The weekly one-year beta is 1.39, while the weekly two-year beta is 1.67. Longer-term measures like the two-week two-year beta and monthly two-year beta are 1.91 and 1.90, respectively. These figures indicate that the Epigral share price has generally shown higher volatility compared to the broader market, especially over shorter time frames.

Epigral Limited Sectoral Relevance and Peer Positioning

Epigral’s sector relevance stems from its scale in chlor-alkali and derivative chemicals, backward integration, and operational efficiency, establishing it as a key player supporting India’s chemical manufacturing ecosystem. Peer comparisons with companies like Gujarat Alkalies and Chemicals Ltd., Chemplast Sanmar Ltd., Galaxy Surfactants Ltd., Vinati Organics Ltd., and Atul Ltd. focus on product portfolio, margin profiles, capacity expansion, and market share rather than short-term stock moves. These benchmarks help assess operational scale, cost structures, and cyclical positioning. Institutional tracking of realizations, feedstock costs, and demand trends further highlights Epigral’s importance within India’s broader chemical markets.

Epigral’s sectoral importance is also reflected in financial and market metrics that demonstrate its scale, stability, and cyclical impact.

The Epigral P/E ratio demonstrates how the market values the company’s earnings relative to its cyclical profitability. The P/E ratio was 11.10 in March 2023, increased to 23.30 in March 2024, and moderated to 22.55 in March 2025. The trailing twelve-month P/E stands at 13.11. Historically, the P/E has fluctuated, reaching its highest in the last five years at 23.30 in March 2024, reflecting peak earnings valuation, and its lowest at 0 in March 2021, prior to its listing. These trends show valuation adjustments aligned with chemical sector cycles and the company’s earnings visibility.

Alongside valuation, Epigral EPS highlights operational performance and income generation. EPS grew from ₹24.27 in March 2021 to ₹60.84 in March 2022, and further to ₹85.03 in March 2023. It decreased to ₹47.14 in March 2024 before recovering to ₹82.91 in March 2025. This volatility in EPS corresponds closely to fluctuations in product realizations, raw material costs, and plant operating rates, providing insight into the company’s performance relative to peers.

Epigral market cap underscores its prominence within the chemical sector. Epigral’s market cap was ₹16.89 billion at its listing in August 2021. It increased significantly to ₹81.80 billion by December 2024, before decreasing to ₹44.29 billion as of February 2026. This market cap history reflects the stock’s volatility, influenced by sector tailwinds, followed by corrections. Its sizeable valuation attracts thematic institutional interest and index-linked investment flows within the small-cap and materials segments.

Finally, Epigral earnings trajectory demonstrates growth amidst cyclicality. Total revenue grew from ₹828.60 crore in March 2021 to ₹2,550.13 crore in March 2025. Net income followed a similar path, increasing from ₹100.84 crore in March 2021 to ₹356.70 crore in March 2025, albeit with a dip in March 2024. These trends reflect the company’s expansion, scale-driven operations, and positioning relative to other chemical manufacturers in India, with performance closely tied to industry cycles.

Summary

Epigral Limited is a significant manufacturer in the Indian chlor-alkali and derivatives sector. The Epigral share price is influenced by sector-specific drivers like product realizations and input costs. Its stock performance shows volatility with long-term growth, reflected in its listing history, index inclusions, and financial metrics such as P/E, EPS, and market cap. The company holds relevance for thematic portfolios, with ownership from various institutional investors. Its peer positioning within the chemical industry provides a context for evaluating its operational and market performance.

https://app.originality.ai/home/scan/42612893